Mirati therapeutics and aadi bioscience partner to evaluate the combination of adagrasib with nab-sirolimus in patients with advanced non-small cell lung cancer and other solid tumors with a kras[g12c] mutation

San diego and los angeles , oct. 12, 2022 /prnewswire/ -- mirati therapeutics, inc. (nasdaq: mrtx), a clinical-stage targeted oncology company, and aadi bioscience, inc. (nasdaq: aadi), a commercial stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mtor pathway genes, today announced a clinical collaboration to evaluate the combination of adagrasib, a krasg12c selective inhibitor, and nab-sirolimus, a small molecule mtor inhibitor complexed with human albumin in kras g12c mutant non-small cell lung cancer (nsclc) and other solid tumors. the primary objective of this multi-center, single-arm, open-label phase 1/2 trial is to determine the optimal dose and recommended phase 2 dose for the combination of adagrasib and nab-sirolimus in patients with krasg12c - mutant solid tumors.
AADI Ratings Summary
AADI Quant Ranking